Physician profile
Manuel Vargas
NPI 1366838948
$3,696.28
in general payments reported to CMS, 2019-2025
13 companies · $807 in 2025
The $807 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $113 · 2021: $435 · 2022: $629 · 2023: $624 · 2024: $845 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.42 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,057.62 | 2021-2025 | |
| Abbvie INC. | $948.89 | 2020-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $725.92 | 2020-2025 | Krystexxa, Otezla |
| Horizon Therapeutics Plc | $236.94 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $173.99 | 2024-2025 | Tremfya |
| Genzyme Corporation | $140.89 | 2025 | |
| Ucb, INC. | $118.14 | 2021-2024 | Cimzia |
| Radius Health, INC. | $111.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.09 | 2024-2025 | Sotyktu |
| Pfizer INC. | $54.28 | 2019-2025 | |
| Lilly USA, LLC | $31.09 | 2021 | |
| Qiagen, LLC | $23.18 | 2021 | |
| Glaxosmithkline, LLC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.